Search: onr:"swepub:oai:DiVA.org:uu-426099" >
Tumour Growth Rate ...
Tumour Growth Rate to predict the outcome of patients with Neuroendocrine Tumours : Performance and sources of variability
-
Dromain, Clarisse (author)
-
- Sundin, Anders, 1954- (author)
- Uppsala universitet,Radiologi
-
Najran, Pavan (author)
-
show more...
-
Vidal Trueba, Hector (author)
-
Dioguardi Burgio, Marco (author)
-
- Crona, Joakim (author)
- Uppsala universitet,Endokrin tumörbiologi
-
Opalinska, Marta (author)
-
Carvalho, Luciana (author)
-
Franca, Regis (author)
-
Borg, Philip (author)
-
Vietti Violi, Naik (author)
-
Schaefer, Niklaus (author)
-
Lopez, Carlos (author)
-
Pezzutti, Daniela (author)
-
de Mestier, Louis (author)
-
Lamarca, Angela (author)
-
Costa, Frederico (author)
-
Pavel, Marianne (author)
-
Ronot, Maxime (author)
-
show less...
-
(creator_code:org_t)
- 2020-07-27
- 2021
- English.
-
In: Neuroendocrinology. - : S. Karger. - 0028-3835 .- 1423-0194. ; 111:9, s. 831-839
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- INTRODUCTION: Tumor growth rate (TGR), percentage of change in tumor volume/month, has been previously identified as an early radiological biomarker for treatment monitoring in neuroendocrine tumors (NETs) patients. We assessed the performance and reproducibility of TGR 3 months (TGR3m) as a predictor factor of progression-free survival (PFS), including the impact of imaging method and reader variability.METHODS: Baseline and 3-months (±1month) CT/MRI images from patients with advanced, grade 1-2 NETs were retrospectively reviewed by 2 readers. Influence of number of targets, tumor burden and location of lesion on the performance of TGR3m to predict PFS was assessed by uni/multivariable Cox regression analysis. Agreement between readers was assessed by the Lin's concordance coefficient (LCC) and Kappa (KC).RESULTS: A total of 790 lesions were measured in 222 patients. Median PFS was 22.9 months. On univariable analysis, number of lesions (DISCUSSION/CONCLUSION: TGR3m is a robust and early radiological biomarker able to predict PFS. It may be used to identify patients with advanced NETs who require closer radiological follow-up.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Dromain, Clariss ...
-
Sundin, Anders, ...
-
Najran, Pavan
-
Vidal Trueba, He ...
-
Dioguardi Burgio ...
-
Crona, Joakim
-
show more...
-
Opalinska, Marta
-
Carvalho, Lucian ...
-
Franca, Regis
-
Borg, Philip
-
Vietti Violi, Na ...
-
Schaefer, Niklau ...
-
Lopez, Carlos
-
Pezzutti, Daniel ...
-
de Mestier, Loui ...
-
Lamarca, Angela
-
Costa, Frederico
-
Pavel, Marianne
-
Ronot, Maxime
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Neuroendocrinolo ...
- By the university
-
Uppsala University